Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins.
Pancreatic RNase injected into Xenopus oocytes abolishes protein synthesis at concentrations comparable to the toxin ricin yet has no effect on oocyte protein synthesis when added to the extracellular medium. Therefore RNase behaves like a potent toxin when directed into a cell. To explore the cytotoxic potential of RNase toward mammalian cells, bovine pancreatic ribonuclease A was coupled via a disulfide bond to human transferrin or antibodies to the transferrin receptor. The RNase hybrid proteins were cytotoxic to K562 human erythroleukemia cells in vitro with an IC50 around 10(-7) M whereas greater than 10(-5) M native RNase was required to inhibit protein synthesis. Cytotoxicity requires both components of the conjugate since excess transferrin or ribonuclease inhibitors added to the medium protected the cells from the transferrin-RNase toxicity. Compounds that interfere with transferrin receptor cycling and compartmentalization such as ammonium chloride decreased the cytotoxicity of transferrin-RNase. After a dose-dependent lag period inactivation of protein synthesis by transferrin-RNase followed a first-order decay constant. In a clonogenic assay that measures the extent of cell death 1 x 10(-6) M transferrin-RNase killed at least 4 logs or 99.99% of the cells whereas 70 x 10(-6) M RNase was nontoxic. These results show that RNase coupled to a ligand can be cytotoxic. Human ribonucleases coupled to antibodies also may exhibit receptor-mediated toxicities providing a new approach to selective cell killing possibly with less systemic toxicity and importantly less immunogenicity than the currently employed ligand-toxin conjugates.
Biochemistry Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20896.
S M
SM
Rybak
S K
SK
Saxena
E J
EJ
Ackerman
R J
RJ
Youle
D000643:Ammonium Chloride / Q000494:pharmacology; D000818:Animals; D016923:Cell Death / Q000187:drug effects; D002460:Cell Line; D002999:Clone Cells; D006801:Humans; D000922:Immunotoxins / Q000633:toxicity; D066298:In Vitro Techniques; D008845:Microinjections; D008985:Monensin / Q000494:pharmacology; D009865:Oocytes; D014176:Protein Biosynthesis; D011500:Protein Synthesis Inhibitors / Q000633:toxicity*; D012260:Ribonucleases / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000633:toxicity*; D013997:Time Factors; D014168:Transferrin / Q000737:chemistry; D014982:Xenopus laevis
D000922:Immunotoxins; D011500:Protein Synthesis Inhibitors; D014168:Transferrin; D000643:Ammonium Chloride; D008985:Monensin; D012260:Ribonucleases